13th Asian & Oceanian Epilepsy Congress (AOEC)

Industry and sponsors

The Asian & Oceanian Epilepsy Congress provides an educational environment dedicated to the exchange of scientific research, training and learning from across the region.

Take advantage of exposure to an interested and relevant audience. Sponsors and their representatives will be in a position to interact virtually with thousands of international professionals and there are many and varied opportunities for companies interested in supporting the congress.

A virtual industry exhibition will also be held in conjunction with the congress. The exhibition is an integral part of the congress, affording delegates an opportunity to learn about new products and services in the field of epilepsy. Delegates will have the opportunity to explore the exhibits in a unique virtual platform and expand their learning not only during the congress but also post congress too in an on demand setting.

Why you can’t miss the virtual 13th AOEC:

• Communicating with attendees: Our virtual platform will create opportunities to speak to our international community in 1-2-1, group, and session hall formats
• Demonstrations: The virtual exhibition hall and innovation showcases will allow you to effectively demonstrate your products
• Follow-up: The technology will allow you to collate interested leads and follow-up with online contacts
• Large online community: ILAE and IBE have a large online community within the Asian and Oceanian region, reaching live audiences of 5000+, therefore you will be introduced to more attendees interested in your company
• Cost-effective: Our packages have been adjusted to offer even more opportunities for your company to reach epilepsy specialists from across the region and beyond and to represent your brand internationally
• Support: The 13th AOEC Secretariat team have vast experience of online events and will support you through the process so that the event is successful for you
• Exposure: Your company will have longer exposure to our attendees as the virtual platform will be open for two months after the live congress ensuring long term visibility during this period of restricted travel and physical congresses
• Innovation: A digital platform allows you to be more creative with content and interaction
• Compliance: Your videos and lectures can be pre-recorded which will make it easier for your compliance team to approve them
• Analytics: The platform will produce more analytics on your booth and education sessions, and allow you to identify trends, engagement patterns and assess ROI

For further information on industry support and sponsorship opportunities at the 13th AOEC, please contact the 13th AOEC Secretariat team on aoec@epilepsycongress.org

Industry Sponsors

Eisai

Eisai is a global research and development-based pharmaceutical company striving for SEIZURE FREEDOM to people living with epilepsy. It is supported throughout the company by our guiding philosophy of human health care (hhc) which is to “give first thought to patients and their families and to increasing the benefits health care provides”.

UCB

UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system. With more than 8300 people in approximately 36 countries, UCB generated revenue of € 5.3 billion in 2020.

BioMarin

BioMarin has been pioneering rare disease for more than two decades, with multiple commercialized products and a growing pipeline of product candidates for serious and life-threatening rare genetic diseases.

At BioMarin, we view ourselves as a team of pioneers—willing to take risks in the quest to find new solutions to address the biggest challenges in rare disease and motivated by the desire to help improve the lives of patients with unmet medical needs.

GW Pharmaceuticals

GW Pharmaceuticals is a UK-based biopharmaceutical company that has established a world-leading position in cannabinoid science and medicine and was listed as one of TIME magazine’s ‘50 Genius Companies Inventing the Future, 2018’. Our mission is to unlock the potential of the cannabis plant through rigorous scientific investigations and extensive clinical trials, to improve the lives of seriously ill patients. Our pioneering work has led to the regulatory approval of world-first, potentially life-improving, cannabis-based medicines.
Patients are our key focus, and improving their quality of life is our motivation.

Job code: VV-MED-20116
Date of preparation: May 2021

Industry Sessions

Satellite Symposia | Webinars

Satellite Symposia

Friday 11 June; 17:30-18:30 JST - Hall 1: Fukuoka
Eisai: Patient’s reality during COVID-19: treatment strategy considering comorbid conditions
Chair: Kiyohito TERADA (Japan)
Speaker: Manuel TOLEDO (Spain)
Live Q&A with the Panel

Friday 11 June; 17:30-18:30 JST - Hall 2: Tokyo
UCB: The value of sodium channel blockers for IGE with GTCS: new evidence for Vimpat® (lacosamide)
Speaker: Terry O’BRIEN (Australia)
Speaker: Philippe RYVLIN (France)
Speaker: Hideaki SHIRAISHI (Japan)
Live Q&A with the Panel

Saturday 12 June; 17:30-18:30 JST - Hall 1: Fukuoka
Eisai: Precision medicine: AMPA biology from basic science to clinical practice
Chair: Naoki AKAMATSU (Japan)
Pathogenesis and treatment progress of post-stroke epilepsy: role of Glutamate AMPA receptor
Speaker: Qun WANG (China)
Age-related etiology, treatment, and Glutamate-AMPA relationship between epilepsy and dementia
Speaker: William Chin Wei HUANG (Taiwan)
Live Q&A with the Panel

Saturday 12 June; 17:30-18:30 JST - Hall 2: Tokyo
UCB: Epilepsy and pregnancy: balancing opportunities and challenges
Chair: Torbjörn TOMSON (Sweden)
Co-chair: Xiaoqui SHAO (China)
Speaker: Hideyuki OHTANI (Japan)
Speaker: Sanjeev THOMAS (India)
Live Q&A with the Panel

Saturday 12 June; 17:30-18:30 - Hall 3: Tokyo
BioMarin: Differential diagnosis and treatment for early-onset pediatric epilepsies
Speaker: Andreas HAHN (Germany)

Webinars

Friday 11 June; 09:30-09:45 JST - Hall 2: Tokyo
UCB: The relevance of mood and psychiatric symptoms for the selection of anti-seizure medications
Speaker: Bettina SCHMITZ (Germany)

Saturday 12 June; 09:30-09:45 JST - Hall 2: Tokyo
UCB: Advancing treatment in PGTCS: adjunctive VIMPAT® (lacosamide) in patients (≥4 years of age) with IGE in a novel time to event trial
Speaker: Jacqueline FRENCH (USA)
Live Q&A

Sunday 13 June; 09:30-09:45 JST - Hall 2: Tokyo
UCB: Physician burnout: an unmet need
Speaker: Raman SAGGU (Germany)